| Q24594047 | Advancements in MR imaging of the prostate: from diagnosis to interventions |
| Q37300338 | Advances in MR spectroscopy of the prostate |
| Q31061313 | Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. |
| Q45309733 | Automatic conformal prescription of very selective saturation bands for in vivo 1H-MRSI of the prostate |
| Q37783670 | Choline PET/CT for prostate cancer: Main clinical applications |
| Q64993825 | Clinical Significance of Multiparametric Magnetic Resonance Imaging as a Preoperative Predictor of Oncologic Outcome in Very Low-Risk Prostate Cancer |
| Q58078877 | Clinical significance and predictors of oncologic outcome after radical prostatectomy for invisible prostate cancer on multiparametric MRI |
| Q60929556 | Clinical significance of multiparametric MRI and PSA density as predictors of residual tumor (pT0) following radical prostatectomy for T1a-T1b (incidental) prostate cancer |
| Q37401554 | Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer |
| Q39554008 | Could Magnetic Resonance Imaging Help to Identify the Presence of Prostate Cancer Before Initial Biopsy? The Development of Nomogram Predicting the Outcomes of Prostate Biopsy in the Chinese Population |
| Q36866123 | Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer |
| Q38837802 | DCE MRI of prostate cancer. |
| Q34742733 | Diffusion-weighted MRI and its role in prostate cancer |
| Q38468586 | Effect of Prostate Biopsy Hemorrhage on MRDW and MRS Imaging |
| Q40079299 | Effects of post biopsy digital rectal compression on improving prostate cancer staging using magnetic resonance imaging in localized prostate cancer. |
| Q36605752 | Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate |
| Q42051192 | Fast T2*-weighted MRI of the prostate at 3 Tesla. |
| Q35763119 | Five-point Likert scaling on MRI predicts clinically significant prostate carcinoma |
| Q37875083 | Imaging in prostate cancer |
| Q36469177 | Imaging localized prostate cancer: current approaches and new developments. |
| Q38479113 | Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine |
| Q36460818 | Imaging techniques for prostate cancer: implications for focal therapy |
| Q38528397 | Implementation of Multi-parametric Prostate MRI in Clinical Practice. |
| Q53083265 | Incremental value of T2-weighted and diffusion-weighted MRI for prediction of biochemical recurrence after radical prostatectomy in clinically localized prostate cancer. |
| Q38190885 | Interpretation and reporting multiparametric prostate MRI: a primer for residents and novices |
| Q53464860 | Is endorectal coil necessary for the staging of clinically localized prostate cancer? Comparison of non-endorectal versus endorectal MR imaging. |
| Q63966236 | L’IRM du cancer de la prostate : un changement de paradigme |
| Q37270567 | MR imaging of the prostate in clinical practice |
| Q79190064 | Magnetic resonance imaging and spectroscopy of prostate cancer |
| Q40133335 | Magnetic resonance spectroscopy imaging-directed transrectal ultrasound biopsy increases prostate cancer detection in men with prostate-specific antigen between 4-10 ng/mL and normal digital rectal examination |
| Q38114017 | Mapping of prostate cancer by 1H MRSI. |
| Q37719273 | Modalities for imaging of prostate cancer |
| Q37406508 | Multidisciplinary functional MR imaging for prostate cancer |
| Q53081178 | Multiparametric MR imaging of peripheral zone prostate cancer: effect of postbiopsy hemorrhage on cancer detection according to Gleason score and tumour volume. |
| Q46012032 | Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology. |
| Q38830576 | Multiparametric MRI of the prostate gland: technical aspects. |
| Q38178850 | Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer: current applications and strategies |
| Q36761055 | Multiparametric magnetic resonance imaging of prostate cancer |
| Q26859699 | Multiparametric magnetic resonance imaging of the prostate: current concepts |
| Q38664945 | Navigating MRI-TRUS fusion biopsy: optimizing the process and avoiding technical pitfalls. |
| Q37242030 | New horizons in prostate cancer imaging |
| Q36456144 | New imaging techniques in prostate cancer |
| Q36387925 | Nonvisible tumors on multiparametric magnetic resonance imaging does not predict low-risk prostate cancer. |
| Q34611905 | Peripheral zone prostate cancer. Pre-treatment evaluation with MR and 3D ¹H MR spectroscopic imaging: correlation with pathologic findings. |
| Q46567823 | Practical aspects of prostate MRI: hardware and software considerations, protocols, and patient preparation |
| Q41831958 | Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles |
| Q35722781 | Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer |
| Q33954515 | Prostate MRI and 3D MR spectroscopy: how we do it |
| Q36809840 | Prostate cancer detection: magnetic resonance (MR) spectroscopic imaging |
| Q57385830 | Prostate cancer vs. post-biopsy hemorrhage: Diagnosis with T2- and diffusion-weighted imaging |
| Q63966486 | Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? |
| Q38089710 | Role of MRI in prostate cancer detection |
| Q51757934 | Significance of postbiopsy hemorrhage observed on preoperative magnetic resonance imaging in performing robot-assisted laparoscopic radical prostatectomy. |
| Q27027567 | Targeted prostate biopsy: value of multiparametric magnetic resonance imaging in detection of localized cancer |
| Q51710859 | The effects of the period between biopsy and diffusion-weighted magnetic resonance imaging on cancer staging in localized prostate cancer. |
| Q38283233 | The optimal timing of post-prostate biopsy magnetic resonance imaging to guide nerve-sparing surgery |
| Q42140991 | The predictability of T3 disease in staging MRI following prostate biopsy decreases in patients with high initial PSA and Gleason score |
| Q26849794 | The role of magnetic resonance imaging in the diagnosis and management of prostate cancer |
| Q34570356 | Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer |
| Q36106249 | Value of T1/T2-weighted magnetic resonance imaging registration to reduce the postbiopsy hemorrhage effect for prostate cancer localization |
| Q35985579 | Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer |
| Q47853024 | Value of three-dimensional T2-weighted turbo spin-echo imaging with tissue-specific variable refocusing flip angle for 3-T magnetic resonance imaging of prostate cancer: comparison with conventional two- and three-dimensional T2-weighted turbo spin- |
| Q84566682 | [Imaging diagnostics of the prostate] |
| Q82583977 | [MRI and staging evaluation of prostate cancer] |